Elsevier

Annals of Oncology

Volume 32, Issue 3, March 2021, Pages 298-308
Annals of Oncology

Special Article
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

https://doi.org/10.1016/j.annonc.2020.11.008Get rights and content
Under an Elsevier user license
open archive

Highlights

  • This updated ESMO Clinical Practice Guideline provides key recommendations on the management of follicular lymphoma.

  • Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad, including levels of evidence and grades of recommendation where applicable.

  • In localised stages, combination of radiation and rituximab monotherapy may be considered.

  • In advanced stages, either obinutuzumab or rituximab may be combined with chemotherapy.

  • In early relapses, a switch of chemotherapy and antibody is recommended. In younger patients, an autologous stem-cell transplantation should be discussed.

  • In older patients with either early, first or later relapses, lenalidomide in combination with rituximab may be considered.

Key words

follicular lymphoma
chemotherapy
radiotherapy
antibody
lenalidomide

Cited by (0)

Note: These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA).

Approved by the ESMO Guidelines Committee: August 2002, last update June 2020. This publication supersedes the previously published version—Ann Oncol 2016; 27 (Suppl 5) v83-v90.